{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"data_sharing_plan":["IPD Sharing (as of August 2023): No"],"condition":["Colorectal Neoplasms","MSI-H Colorectal Cancer"],"disease":["Colorectal Neoplasms","Msi-h Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/71370"],"location":["United States"],"study_start_month":["8"],"keyword":["Pembrolizumab","Immune checkpoint inhibitor","Vascular endothelial growth factor receptor (VEGFR)","Multi-kinase inhibitor","Receptor tyrosine kinases","Anti-PD1 blockade"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer","description":"This is a trial of Regorafenib in combination with pembrolizumab for patients with MSI-H colorectal cancer consisting of lead-in phase examining preliminary efficacy and safety, followed by a randomized phase to further examine efficacy.","dates":{"creation":"2023-08-15"},"accession":"71370","cross_references":{"ClinicalTrials___gov":["NCT06006923"]}}